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Abstract The CYP2CI8 gene was investigated in order to 
characterize its molecular basis in the CYP2C subfamily. A 
mutation of the CYP2C18 gene was identified at the 5'-flanking 
region of the gene, which could be detected by digestion with 
DdeI. The allele frequency of the mutant CYP2C18 gene was 
21.4%. Genotypes of the polymorphic DdeI site of the CYP2C18 
gene were found to be completely consistent with that of the 
polymorphic CYP2C19 gene (the ml mutant). The CYP2CI8 
and CYP2CI9 genes were suggested to be linked and located 
close together on the chromosome. Clones containing the 5'- 
flanking region of a member of the CYP2C subfamily were 
obtained from the PCR products from human genomic DNA. 
The nucleotide sequence of the clone proved to be 90.5% identical 
to the corresponding region of the CYP2C18 gene. This is very 
likely to be a novel member of the CYP2C subfamily. 
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1. Introduction 
In human liver, many clinically used drugs such as mephen- 
ytoin and hexobarbital re metabolized by the CYP2C sub- 
family [1]. The human CYP2C subfamily consists of at least 4 
members (CYP2C8, CYP2C9, CYP2C18, CYP2C19) [1,2]. 
Extensive metabolizer (EM) and poor metabolizer (PM) poly- 
morphism for mephenytoin [3,4] is well known and has been 
studied extensively. It has been shown that CYP2C19 is a 
candidate for mephenytoin 4'-hydroxylation [5,6]. However, 
the role of CYP2C18 and the relationships between the other 
CYP2C subfamily members and the CYP2C18 gene have not 
been clearly demonstrated. Further study is required to under- 
stand the characteristics of the CYP2C subfamily. 
In the present study, we investigated the CYP2C18 gene to 
characterize the molecular basis of the CYP2C18 gene and to 
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search for other members of the CYP2C subfamily. A novel 
mutation was identified at the 5'-flanking region of the 
CYP2C18 gene and the mutation was found to be completely 
linked to the ml mutation [7] of the polymorphic CYP2C19 
gene. Moreover, the 5'-flanking region and each exon of the 
CYP2C18 gene were analyzed by the PCR method and SSCP 
analysis, and a novel variant of the 5'-flanking region of the 
CYP2C subfamily was obtained and sequenced. 
2. Materials and methods 
2.1. Genomic DNA extraction 
Human genomic DNA was extracted from leukocyte nuclei of per- 
ipheral blood obtained from 56 healthy volunteers according to the 
method of Kan and Dozy [8]. 
2.2. PCR amplification for fragments of CYP2C18 genes 
A PCR for the CYP2C18 gene was carried out using the following 
primers (Fig. 1): primers 1 and 2 for fragment 1, primers 3and 4 for 
fragment 2, primers 5 and 6 for fragment 3, primers 7 and 8 for 
fragment 4, primers 9 and 10 for fragment 5, primers 11 and 12 for 
fragment 6, primers 13 and 14 for fragment 7, primers 15 and 16 for 
fragment 8, primers 17 and 18 for fragment 9. Each was conducted in
a total volume of 50 Ixl in the presence of 1.25 mM magnesium chlor- 
ide, 10 mM Tris-HC1 (pH 8.3), 200 ~tM of each dNTP, 5 pmol of each 
primer [2,9] as shown below: primers 1 (5'-AGTCTAAGCCACTC- 
CATATT-Y) and 2 (5'-TGACTCTGACTGTGACTAGT-Y), or 3 
(5'-GCTCTGCTTCAGACTAGTTA-3') and 4 (5'-ATGTCTGTAC- 
TTCCATGTTT-3'), or 5 (5'-ATATAGACCAAATACTGAGT-3') 
and 6 (5'-GATCATTACACATTCTGTGC-3'), or 7 (5'-CCTCACC- 
CTGTGATCCCACT-3') and 8 (5'-CTGGATAATCCTGAGGTT- 
TT-3'), or 9 (5'-CAGGTCTGCAATAATI'TCCC-3') and 10 (5'- 
CTGTTCCAT'I'TTGATCAGGA-3'), or 11 (5'-GAAAAGCACAAT- 
CAACAGTC-3') and 12 (5'-TGTGACCTCTGGGTACTTCA-3'), or 
13 (5'-GCTAAAGTCCAGGAAGAGAT-3') and 14 (5'-CTTGGGG- 
ATGAGGTAGTTTT-3'), or 15 (5'-GGCACGACCATAATAACA- 
TC-3') and 16 (5'-TGCTGAGAAAGGCATGAAGT-3'), or 17 (5'- 
GGAAAACGGATGTGTATGGG-3') and 18 (5'-TTGCAGGTGA- 
CAGCACAGGA-3'). To each was added 400 ng genomic DNA and 
0.5 U Taq DNA polymerase (Promega, Co., Madison, WI, USA) or 
Pfu DNA polyrnerase (Stratagene, La Jolla, CA, USA) for cloning. 
The conditions for annealing, polymerization a d denaturation were 
52°C for 2 min, 72°C for 2 min, and 94°C for 1 min, respectively. The 
number of cycles amplified was 40. 
2.3. Restriction enzyme digestion of the PCR products 
DNA fragments ofthe CYP2C18 gene were digested by the follow- 
ing restriction enzymes for 2 h at 37°C to find RFLP, and analyzed by 
agarose gel electrophoresis: ApaI, AccI, AluI, AvaI, AfaI, AfllII, BfaI, 
BgllI, BclI, BamHI, BanlII, DdeI, EcoRI, EcoRV, FokI, HaelII, 
HinelI, HpalI, HphI, Hinfl, Hhal, HindlII, KpnI, MbolI, Mnll, 
NotI, NcoI, NruI, PstI, PvulI, SalI, ScrFI, Sau3A, SpeI, SphI, 
SmaI, SspI, SacI, SacII, TaqI, Xhol and XbaI. 
2.4. Determination f rgenotypes ofthe CYP2C18 gene and CYP2C19 
gene 
The genotype at the DdeI site in the 5'-flanking region of the 
CYP2C18 gene was determined by digesting the PCR amplified frag- 
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Fig. 1. Amplification for the fragments of the CYP2C18 gene. Locations of the fragments amplified by PCR are shown. 
ment 1 with DdeI and analyzed by agarose gel electrophoresis a
shown in Fig. 2. 
Genotype analysis of the polymorphic CYP2C19 gene was also 
performed to investigate the relationship of the genotype between 
the polymorphic CYP2C18 gene and the polymorphic CYP2C19 
gene by a modification of the method of de Morais et al. [7]. Primers 
sets used in the study were primers 1 (5'-AATTACAACCA- 
GAGCTTGGC-3') and 2 (5'-TATCACTTTCCATAAAAGCAAG- 
3') in the CYP2C19 gene. A PCR reaction was performed in a total 
volume of 50 pJ in the presence of 10 pmol of each primer, 1.25 mM 
magnesium chloride, 10 mM Tris-HC1 (pH 8.3), 200 p.M of each 
dNTP, 400 ng of genomic DNA and 0.5 U of Taq DNA polymerase 
(Promega Co., Madison, WI, USA). The conditions for annealing, 
polymerization and denaturation were 55°C for 1 min, 72°C for 
1 min, and 94°C for 1 min, respectively. The number of cycles ampli- 
fied was 30. The amplified fragment was digested with Sinai (New 
England Biolab, Beverly, MA, USA) and was electrophoresed on 2% 
agarose gel. 
2.5. Cloning of the PCR products and SSCP analysis 
About 30 ng of the PCR products of the CYP2C18 gene were 
ligated with 50 ng of pT7Blue T-vector (Novagen, Madison, WI, 
USA) and transformed with NovaBlue cell. Plasmid DNA from the 
white colony was analyzed for restriction map and SSCP. 
SSCP analysis was conducted as follows [10]. The insert of plasmid 
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DNA was amplified by the secondary PCR with the same primers 
used as in the first amplification from genomic DNA. The secondary 
PCR was performed in a total volume of 25 pl in the presence of 1.5 
mM magnesium chloride, 10 mM Tris-HC1 (pH 8.3), 200 p.M of each 
dNTP, 5 pmol of each primer, about 1 ng of plasmid DNA and 0.25 
U Pfu DNA polymerase (Stratagene, La Jolla, CA, USA). The con- 
ditions for annealing, polymerization and denaturation were the same 
as in the first PCR. The number of amplified cycles was 15.2 p.1 of the 
PCR reaction was mixed with 30 ~tl of formamide-dye buffer (0.1% 
bromophenol b ue, 0.1% xylene cyanol FF, 20 mM EDTA in forma- 
mide) and denatured for 5 min at 80°C. 2 ~tl of the mixture was 
electrophoresed on a 5% acrylamide gel at 150 V for 8 to 10 h at 
4°C. Separated DNA was stained with a Silver Stain Plus Kit (Bio- 
Rad, Tokyo, Japan). 
2.6. Sequencing 
Determination of the nucleotide sequence was performed by the 
dideoxy chain-termination method [11] with a Bcabest sequencing 
primer (5'-CGCCAGGGTTTTCCCAGTCACGAC-3') using a Se- 
quenase Version 2.0 kit (United States Biochemical, Cleveland, OH, 
USA) on both strands. 
3. Results and discussion 
3.1. Searching for a polymorphic allele of  the CYP2C18 gene 
The 5'-f lanking region and 9 exons of the CYP2C18 gene 
were amplified by PCR (Fig. 1) and a polymorphic allele was 
surveyed by 42 restriction enzymes. For  each fragment, PCR 
products from more than 16 individuals were analyzed for 
RFLP.  Only a DdeI site, which is situated 479 bp upstream 
Ha Ha P B 
CYP2C18 I III III 
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H2CYM I I I I I  I I 
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Fig. 2. Restriction maps for fragment 1 of the CYP2C18 gene for 
wild type and mutant type. The DdeI digestion patterns for three 
genotypes are shown in the lower panel. 
Ha 
CYP2C8 I I II 
D D D 
Ha 
CYP2C9 I I J I I  
D D D D 
B:BglII, D: Dde l, Ha: Hae lll, P: Pst l 
Fig. 3. Restriction map for the H2CYM clone. The restriction maps 
of the corresponding regions for CYP2C18, CYP2C8 and CYP2C9 
are shown for comparison. A polymorphic DdeI site in the 
CYP2C18 gene is underlined. 
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H2CYM : AGTCTAAGCC ACTCCATAIT GATI"I'ATITC CCTTCCTGTG CATGTGI"rAA AGGTAGGAAT t i t iCACTGT GGGCATATTT 80 
2C18: C - 862 
H2CYM : AGGCAAGCTC CCTGTGCAAG TrccC ITATC TGCACAAAAC ATCTAGTGTA AGTACTTGGG G i i i i i GTGG A ITGGGCAAT 160 
2C18: - 782 
H2CYM :GACCTGGAAGGGI"rGGAGGTTCTCTGGGGACCCITCCCIT  ACTGCCTGCCTAAAGCAAGCTGGCTAACTC CCCTCAATAG 240 
2C18: T T -702 
H2CYM : GATAAACAI-r A ITGTACATA CAAGGGATAT AATACATAGA "I'rGCCCTCAA AGTTATAITT  CCAACTGGTC ATCAATCTAA 320 
2C18: T TG A C C C - 622 
H2CYM : GAATCCAAAC t i t tGAGTAA i i i i t tGATG AAGAAG'I-I-rA c I - rCATTGGT TCTCAAi I i i GGCTGCACAG TGGAACCACC 400 
2C18: A A A AT A T T -542 
H2CYM : TGGGGTGTTT AAAAAAACCT GGGCCTGGCG GGGCGCGCTG GCTCATGCCT GTAATCCCAC CACI"I'rGGAA GGCCGAGGCA 480 
2C18: C G A A C A A G G A . . . . . . . . . . . . .  474 
H2CYM : GGTGGATCAC CTGAGGTCAG GAGI"I-I'GAGA CCAGCCTGAC CAACATGGTG AAACCCCATC TCTGCTAAAA ATAAAAAATC 560 
2C18: . . . . . . . . . . . . . . . . . . . . . . . . . .  G TG C - 420 
H2CYM : ACC - GGACGT GGTGGCACAT GCCTGTAATC CCAGCTATGC TGGAAGCTAA GGCAGGTGAA TCTCI"rGAAC CCAGGAGGCA 639 
2C18: T G A T TG T C C CA G - - -  GT C T A TG-343 
H2CYM : GAGGTTGCAG TGAGCTGAGA TCI"TGCCA'rr GCACTCCAGC CTGGGCAACA AGAGTCGAAA CTCCATCTAA AAACAAACAA 719 
2C18: C T C GGA AC - 264 
H2CYM : ACAACGAAAC AAACAAACAC TTGGGCTCTG CTTCAGACTA G'I-rAAA . . . . . . . . .  CCAGG GTGGGGC'I-I-r GGAAAGGAGA 790 
2C18: A C AC AT C CCAGAATCT ACC . . . .  187 
H2CYM : ACAAGAAAAT AAAACACCI"r An t i i tATCT i i t iCAGTCA GCCAATGI"rC AI-I 'CAGAAGA GAGATTAAAA TGCI"rCT'rrc 870 
2C16: A G C G A G T G -107 
H2CYM : TGACTAGTCA CAGTCAG AGT CA 892 
2C18: - 85 
Fig. 4. Nucleotide sequence of the clone H2CYM. Nucleotide sequence for the corresponding region of CYP2C18 is shown for comparison. 
Only the nucleotide sequences that are different from H2CYM are indicated. The locations of the nucleotide sequences u ed for synthesizing 
primers are underlined. - :  gap site. The nucleotide sequence of H2CYM has been deposited in the GenBank under the accession no. D 78379. 
from the first codon of the CYP2C18 gene, was found to be 
polymorphic while other sites were monomorphic. The restric- 
tion enzyme map and the DdeI digestion patterns of the 5'- 
flanking fragment (fragment 1) are shown in Fig. 2. In the 
wild type homozygote (w/w), heterozygote (w/m) and mutant 
homozygote (m/m), three bands (462 bp, 288 bp and 106 bp), 
four bands (568 bp, 462 bp, 288 bp and 106 bp) and two 
bands (568 bp and 288 bp) were seen, respectively. Ibeanu 
and Goldstein [12] investigated the promoter egion of the 
CYP2C9 and CYP2C18 genes, and showed that the 5'-flank- 
ing region of the CYP2C18 gene had low promotional ctiv- 
ity. Although the polymorphic DdeI site of the CYP2C18 gene 
is located close to the potential AP-2 site [13], the functional 
property of the mutation such as in the expression of the gene 
is not clear and should be analyzed by site-directed mutagen- 
esis. 
3.2. Analysis for genotypes of the CYP2C18 gene and the 
CYP2C19 gene 
The polymorphic DdeI site in the 5'-flanking region of the 
Table 1. Genotype distributions of the DdeI site in the CYP2C18 
gene of the healthy controls 
w/w w/m m/m Total 
Healthy 35 (62.5) 18 (32.1) 3 (5.4) 56 
controls 
Within parentheses are the percentages of the total, w and m indicate 
the wild type gene and mutant type gene, respectively. 
CYP2C18 gene was analyzed for 56 healthy controls and the 
genotypes are shown in Table 1. The allele frequency of the 
mutant CYP2C18 gene was 21.4%. The genotype of the poly- 
morphic CYP2C18 gene was consistent with that of the ml 
mutation [7] of the CYP2C19 gene. This result suggests that 
the CYP2C18 and CYP2C19 genes are linked and closely 
located on the chromosome. 
3.3. Searching for a member of the CYP2C subfamily in the 
human genome 
The faint bands, which were visible when the PCR products 
were digested with several restriction enzymes, could be de- 
rived from the CYP2C subfamily members that are different 
from CYP2C18. The products of PCR were examined in order 
to determine which member of the CYP2C subfamily had 
been amplified. The PCR products from 9 regions were cloned 
into the plasmid, and more than 10 clones from each fragment 
were analyzed by restriction enzyme mapping and SSCP (Ta- 
ble 2). All except for 5 clones from the 5'-flanking fragment 
showed identical restriction maps and SSCP patterns to those 
of CYP2C18. A restriction map of the 5 clones, which was 
different from the corresponding regions of the CYP2C8 or 
CYP2C9 genes, was similar to the CYP2C18 gene as shown in 
Fig. 3. Since the nucleotide sequences of the corresponding 
region for CYP2C19 have not been reported, these 5 clones 
contain the 5'-flanking region which is different from any 
reported genes of the CYP2C subfamily. 
The nucleotide sequence of H2CYM, one of the 5 clones 
Table 2. Number of clones analyzed for restriction enzyme mapping and SSCP 
Fragment No. 1 2 3 4 5 6 7 8 9 
Length (bp) 860 1092 703 159 180 141 189 141 226 
No. of clones 37 (5) 21 15 l0 28 27 9 18 20 
analyzed 
Within parentheses are the numbers of clones different from CYP2C18. 
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described above, has been determined (Fig. 4). The CYP2C18 
gene showed the highest homology to H2CYM. Excluding the 
insertions and deletions, the number of nucleotides that are 
different between CYP2C18 and H2CYM was 76 out of 804 
sites. Therefore, the nucleotide sequence of H2CYM was 
90.5% identical to the corresponding region of the 
CYP2C18 gene. Several conserved sites could be aligned in 
the corresponding regions of the CYP2C8 and CYP2C9 
genes. Since the CYP2C18 gene and H2CYM are 90.5% 
homologous in the 5'-flanking region, there should be no 
nucleotide difference or only minimal differences in the re- 
gions of 9 exons. Alternatively, the exon regions for 
H2CYM were not amplified with the PCR conditions used 
here. The nucleotide sequence of H2CYM is different from 
either CYP2C8 or CYP2C9, however, it is not clear whether 
H2CYM is CYP2C19 or not. Further sequence analysis of the 
CYP2C19 gene or gene corresponding to H2CYM should be 
conducted. 
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